What is Retatrutide: Complete Guide to the Triple Agonist Peptide

Retatrutide is one of the most studied research peptides in recent years in the field of metabolic regulation. Unlike other compounds that act on one or two receptors, Retatrutide functions as a triple agonist, simultaneously interacting with three key metabolic pathways.

In this guide, you will find everything that scientific literature has documented about this compound: what it is, how it works, what studies exist, and what factors to consider when acquiring it for research.

What is Retatrutide?

Retatrutide (also known as LY3437943) is a synthetic peptide originally developed by Eli Lilly and Company and currently under clinical investigation. It is a triple receptor agonist: GLP-1 Receptor (Glucagon-Like Peptide-1), GIP Receptor (Glucose-Dependent Insulinotropic Polypeptide), and Glucagon Receptor.

This unique combination distinguishes it from compounds like Semaglutide (GLP-1 agonist only) or Tirzepatide (dual GLP-1/GIP agonist), making it the metabolic research agent with the broadest action profile available today.

How Does Retatrutide Work? Mechanism of Action

Retatrutide's mechanism of action involves three simultaneous pathways:

1. GLP-1 Agonism

The GLP-1 receptor is key in regulating glucose-dependent insulin secretion, glucagon suppression, and appetite modulation at the hypothalamic level. GLP-1 agonists are well-known in research for their effect on glucose homeostasis and satiety signaling.

2. GIP Agonism

The GIP receptor complements GLP-1 in insulin secretion and also affects lipid metabolism and adipose function. The GLP-1 + GIP combination (as in Tirzepatide) has already demonstrated superior effects to GLP-1 agonism alone in previous studies.

3. Glucagon Agonism

Here is Retatrutide's key difference: glucagon agonism increases energy expenditure, fatty acid oxidation, and thermogenesis. The synergistic interaction of these three pathways is what makes Retatrutide the compound with the greatest interest in metabolic research today.

Published Clinical Studies

Phase 2 Study (Jastreboff et al., NEJM 2023)

The most cited study on Retatrutide is the Phase 2 trial published in the New England Journal of Medicine. The highest dose (12 mg weekly) showed an average reduction of 17.5% of body weight in 24 weeks. Results projected to 48 weeks exceeded 22%. The tolerability profile was comparable to that of other GLP-1 agonists.

Important note: These data are from clinical research and do not constitute a therapeutic indication. Retatrutide is not approved as a drug by any regulatory agency as of the publication date of this article.

Retatrutide vs Other Metabolic Research Peptides

Comparison of compounds: Semaglutide (GLP-1, ~14% weight reduction) | Tirzepatide (GLP-1 + GIP, ~20%) | Retatrutide (GLP-1 + GIP + Glucagon, ~22%) | Cagrilintide (Amylin, ~8% alone).

Considerations for Research with Retatrutide

For scientific research, peptide purity is the most critical factor. The minimum standard accepted in serious research is ≥99% HPLC. Retatrutide for research is generally supplied as lyophilized powder in 10 mg vials. Storage: 2–8°C, avoid freeze/thaw cycles, protect from humidity and direct light.

Where to Acquire Retatrutide for Research in Mexico?

At MVLabs, we offer research-grade Retatrutide with ≥99% HPLC purity, lyophilized presentation in 10 mg vials, with a unique QR code for authenticity verification on each product. Shipping 3–5 business days throughout Mexico, discreet packaging.

Frequently Asked Questions about Retatrutide

Is Retatrutide approved as a medicine in Mexico? No. It is exclusively marketed for scientific research use.

What differentiates Retatrutide from Semaglutide? Semaglutide acts only on the GLP-1 receptor. Retatrutide simultaneously acts on GLP-1, GIP, and glucagon.

What is the minimum recommended purity for research? ≥98% HPLC minimum. MVLabs offers ≥99% HPLC.

How do I verify the authenticity of an MVLabs vial? Each vial includes a unique QR code verifiable at mvlabs.mx/pages/verificar.

Published by MVLabs — Research Peptides in Mexico | mvlabs.mx